PD-1 blockade with pembrolizumab for classical Hodgkin lymphoma after autologous stem cell transplantationPhilippe Armand, Alex F. Herrera, Yi‐Bin Chen et al.|Blood|2019Cited by 187
Relapsed or Refractory Double-Expressor and Double-Hit Lymphomas Have Inferior Progression-Free Survival After Autologous Stem-Cell TransplantationAlex F. Herrera, Philippe Armand, Matthew Mei et al.|Journal of Clinical Oncology|2016Cited by 187
PD-1 blockade for diffuse large B-cell lymphoma after autologous stem cell transplantationMatthew J. Frigault, Robin Joyce, Philippe Armand et al.|Blood Advances|2020Cited by 65
Rituximab/bendamustine and rituximab/cytarabine induction therapy for transplant-eligible mantle cell lymphomaReid W. Merryman, Eric D. Jacobsen, Natasha Edwin et al.|Blood Advances|2020Cited by 58
A multicenter retrospective study of polatuzumab vedotin in patients with large B-cell lymphoma after CAR T-cell therapySushanth Gouni, Paolo Strati, Allison Rosenthal et al.|Blood Advances|2022Cited by 37